UCLA researchers have reported a promising way to improve antibody-drug conjugates, or ADCs, in metastatic castration-resistant prostate cancer, a disease that remains difficult to control once it stops responding to hormone therapy. Their work suggests that pairing ADCs with a drug that blocks BCL-XL can make prostate cancer cells more vulnerable, leading to greater cell […]
Antibody–drug conjugates (ADCs) have transformed therapy in several malignancies, but in advanced prostate cancer they have mostly been evaluated for direct tumor cytotoxicity, with little attention to immune mechanisms that might underpin durable responses. A recent study introduces a new STEAP1‑targeted ADC platform built on vandortuzumab, an antibody directed at six‑transmembrane epithelial antigen of the […]
LIV1, a zinc transporter protein, sits on the surface of 72% of prostate tumors with minimal expression in healthy tissues. This makes it an ideal target for antibody-drug conjugates, a therapeutic class combining antibody specificity with potent cytotoxic payloads. Researchers developed 48D6, a humanized anti-LIV1 monoclonal antibody with substantially improved pharmacokinetics compared to previous versions. […]
In advanced prostate cancer, castration‑resistant and neuroendocrine variants present some of the toughest clinical challenges because they often lose dependence on androgen receptor signaling and become refractory to hormone‑targeted therapies. Within this resistant landscape, MUC1‑C, the C‑terminal subunit of the mucin‑1 oncoprotein, emerges as a promising alternative target. MUC1‑C is aberrantly overexpressed and under‑glycosylated in […]
A promising new experimental drug called NEOK001 (also known as ABL206) is emerging as a potential therapy for advanced cancers that express two specific proteins on their surface: B7‑H3 and ROR1. Among these cancers, prostate cancer is one of the tumor types where early data already show signs of activity, making NEOK001 a candidate of […]
SHR-A1921, also known as tizetatug rezetecan, represents a significant advancement in targeted cancer therapeutics, specifically designed to exploit TROP2 overexpression in aggressive malignancies including prostate cancer. This novel antibody-drug conjugate (ADC) has demonstrated compelling preclinical activity in prostate cancer models and encouraging early clinical results across multiple solid tumors, positioning it as a potential therapeutic […]
ALCO5 is a new way of building “smart” cancer drugs that combine an antibody with a powerful medicine in a single, targeted package. The aim is to hit cancer cells much harder while sparing as much healthy tissue as possible, and to do this with drug types that previously could not be used in these […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy